Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1996 2
1999 1
2003 2
2006 2
2007 1
2008 2
2009 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
FDA drug approval summary: panitumumab (Vectibix).
Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. Giusti RM, et al. Oncologist. 2007 May;12(5):577-83. doi: 10.1634/theoncologist.12-5-577. Oncologist. 2007. PMID: 17522246 Free article. Clinical Trial.
A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology.
Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J. Giusti RM, et al. J Med Genet. 2003 Oct;40(10):787-92. doi: 10.1136/jmg.40.10.787. J Med Genet. 2003. PMID: 14569130 Free PMC article. No abstract available.
Vaginal clear cell adenocarcinoma in the United States.
Trimble EL, Rubinstein LV, Menck HR, Hankey BF, Kosary C, Giusti RM. Trimble EL, et al. Among authors: giusti rm. Gynecol Oncol. 1996 Apr;61(1):113-5. doi: 10.1006/gyno.1996.0107. Gynecol Oncol. 1996. PMID: 8626097
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R. Giusti RM, et al. Clin Cancer Res. 2008 Mar 1;14(5):1296-302. doi: 10.1158/1078-0432.CCR-07-1354. Clin Cancer Res. 2008. PMID: 18316547 Clinical Trial.
14 results